Abstract
Purpose: In many inflammation-driven diseases, blocking IL-1 signaling can be a potential strategy to help restore normal homeostasis. The modified recombinant version of IL-1RA, known by the name Anakinra, which competes with IL-1β is seen as a potential disease modifying osteoarthritis drug (DMOAD). However, as with many therapeutic proteins it shows a short half-life and loss of bioactivity. Currently, this problem is addressed by frequent injections of high doses of therapeutic proteins that is associated with unwanted side effects and patient morbidity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
